# **GREENFERN INDUSTRIES LIMITED**

INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS PERIOD ENDED 30 SEPTEMBER 2024

# GREENFERN INDUSTRIES LIMITED INTERIM CONSOLIDATED REPORT CONTENTS FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024

	Page
Directors report	3-4
Consolidated Statement of Comprehensive Income	5
Consolidated Statement of Financial Position	6
Consolidated Statement of Changes in Equity	7
Consolidated Statement of Cash Flows	8
Notes to the Consolidated Financial Statements	9 - 25
Corporate Information	26

# GREENFERN INDUSTRIES LIMITED DIRECTORS REPORT

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024

The Directors are pleased to present the company's results for the six months ended 30 September 2024.

#### **Financial Results Summary**

Greenfern Industries Limited ("GFI") reports revenue of \$244,438 during the six-month period, which doubled (105%) the prior 6-month period ended 30 September 2023. GFI has begun to focus firmly on medicinal cannabis flower production, which has started to generate revenue in the last 6 months. This has been a long-term process as the New Zealand regulations have been slower and more difficult to navigate than was expected and operational results have been mixed.

In the six months to 30 September 2024 GFI produced a net loss attributable to shareholders of \$0.65 million. This compares with a similar net loss attributable to shareholders for the previous period. The majority of expenses were identified as employee salaries, provision for bad debts in relation to Sustainable Foods and Cannvalate, insurance, depreciation and NZX compliance costs including Board and audit fees. No dividends have been declared or paid for the six months ended 30 September 2024.

The net assets as at 30 September 2024 were NZ\$1.38 million, cash and cash equivalents were NZ\$0.024 million, and the property, plant and equipment were NZ\$2.68 million.

The company remains in a growth stage and will be reliant on continued capital raising to meet its obligations and deliver its business plans.

Since 30 September 2024 the Company has undertaken a wholesale placement, offering 9,000,000 ordinary shares, together with 4,500,000 options to subscribe for an additional ordinary share at \$0.022 at any time in the following 12 months in an attempt to raise \$200,000. To date the offering has raised \$95,000 which has included ongoing support from directors and their associates. All existing shareholders and other investors, that qualify as wholesale investors, are welcome to participate on the same terms.

The company is proposing to undertake a rights issue to all shareholders in December to raise at least \$500,000. As a growth company which is investing in our operations in order to create and extend product lines, shareholder support for the offer will be required for the company to reach its goals and remain a going concern. This is no different to any other company balancing its costs while trying to break ground in this new space.

The company will continue to draw on and build on our sales contracts, future sales funnels, relationships and networks of interested parties but until then we will be relying on raising capital through the support of our shareholders.

#### **Principal Activities**

GFI is an entrepreneurial-led licensed medicinal cannabis, research and biotechnology company, operating out of the purpose-built production facilities in Normanby, South Taranaki. It is powered by the GFI owned onsite hydropower station when river levels permit.

FY2025 will see continued focus on medicinal cannabis, research, development and production for export. Another major focus for 2025 will be the development of a market ready soluble hemp protein powder (Shared GFI/Hemp Connect IP).

## GREENFERN INDUSTRIES LIMITED DIRECTORS REPORT (continued)

#### **Review of Operations and Outlook**

#### 1. Cultivation

• New management was appointed late August 2024, a CEO with six years-experience in the cannabis industry and a trained horticulturist.

• After 12 months of operating the full-scale cultivation facility we had experienced mixed success. The incoming management have now conducted a full review of cultivation processes, genetics and a full analysis of results to date. This identifying the need to refine both our genetics and cultivation procedures. Cultivation was halted, a reset programme developed, and implementation of that programme begun.

• The cultivation reset will identify from 12 selected cultivars the most stable to produce for the European market (>25%THC), for the two-tier Australian market (20-25% and >25%THC) and for the purely medicinal market (high CBD:THC ratio and specific terpene profiles.). The selected genetics will be cultivated under strict cultivation processes to achieve maximum yield per grow room.

Recent changes to the Medicinal Cannabis Regulations has removed barriers, which have worked against the industry for the past 5 years. The requirement is now to meet regulatory requirements of the country receiving the exports and not the more onerous and restrictive NZ standards. This means a reduction in compliance costs and the long regulatory delays and has significantly opened the international export market
Offtake agreements with European and Australian markets are under negotiation.

• To date 6 harvests have been completed and sold to the European and domestic markets, and Greenferm

forecasts production of 50kg from the facility every 12 weeks, starting from early February 2025.

• GFI will also continue with its research and development in its existing test facility to stay up to date with evolving markets and consumer demands.

#### 2. Soluble Hemp Protein Isolate

• GFI has finalised more than two years joint research with Hemp Connect Ltd and Callaghan Innovation as part of BPA (Bio Resource Processing Alliance) funding

• This has resulted in the development of a water-soluble Hemp Protein Isolate. This is a highly sought after single ingredient in the protein market, functional foods and other high commodity markets offering a full amino acid profile and neutral flavour which makes it highly versatile and unique. Final steps are needed to confirm manufacturing processes for commercial scalability, IP protection and market launch.

• It is potentially a world first in this space and therefore has significant upside for the company if scalability trials are successful

•Already there is significant interest in this products potential.

#### 2. Electricity generation

• GFI continues to look at options for development, upgrade and review of river level consents for their hydropower generation plant at Normanby, Taranaki.

• The power station generates renewable power to run GFI's onsite cannabis cultivation facility enabling cost benefits that provide a meaningful margin advantage relative to GFI's peer group. However it is subject to river consent level restrictions and therefore very dependent on the weather.

•Excess power is sold back to the national grid for additional revenue.

• A development opportunity is expected to increase generation capacity from 250Kw to ~950Kw and increase asset book value to approximately \$3.5m, however this will require separate dedicated funding.

Despite continued uncertainty in the global economy and the other setbacks experienced, we remain optimistic about the future of GFI and we continue to explore wider industry opportunities. We will maintain focused on improving the efficiency of our cultivation operations, the development of the soluble hemp protein isolate, and expanding our market presence to achieve our long-term growth objectives.

On behalf of the Board of Directors

Marvin Yee Chairman Mobile 0272553288 Email chair@gfi.nz

### GREENFERN INDUSTRIES LIMITED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024

	Notes	Unaudited 6 Months September 2024 NZ\$	Unaudited 6 Months September 2023 NZ\$
Operating Revenue Cost of Sales	2 3 _	244,438 (140,521)	119,390 (31,634)
Gross profit		103,917	87,756
Other Income		-	48,830
<b>Expenses</b> Selling and Distribution Expenses Administration Expenses	3 3 _	(12,000) (667,622)	(21,514) (647,317)
		(679,622)	(668,831)
Operating loss		(575,705)	(532,245)
Finance Income		-	847
Finance Expense	-	(78,756)	(59,386)
		(78,756)	(58,539)
Loss before income tax		(654,461)	(590,784)
Loss for the year	-	(654,461)	(590,784)
Total comprehensive loss for the year	-	(654,461)	(590,784)
Loss and total comprehensive loss attributable to: Equity holders of the parent		(654,461)	(590,784)
	=	(654,461)	(590,784)
Loss per share: Basic and Diluted Earning per share in NZ\$	5	(0.00559186)	(0.00537775)

The interim financial statements are to be read in conjunction with the notes to the financial statements set out on pages

-

-

### GREENFERN INDUSTRIES LIMITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024

		Unaudited At 30 September	Audited At 31 March
		2024	2024
	Notes	NZ\$	NZ\$
SHAREHOLDERS EQUITY			
Issued share capital	6	10,652,010	10,546,012
Options Reserve		3,068	3,069
Accumulated losses		(9,272,885)	(8,618,425)
Total Equity attributable to shareholders of the company		1,382,193	1,930,656
Represented by:			
CURRENT ASSETS			
Cash and cash equivalents	7	24,074	185,808
Trade, other and related party receivables Provision for bad debts	8	74,648	150,155
Barter card	8 11	(72,923) 14,181	-
Biological Assets	11	2,302	24,355
Prepayments and other current assets	9	18,920	60,247
Total current assets		61,202	420,565
NON-CURRENT ASSETS			
Other financial assets	13	200	200
Barter card	11	-	16,758
Property, plant and equipment	10	2,649,727	2,768,402
Intangible assets	12	9,024	9,499
Total non-current assets		2,658,951	2,794,859
Total assets		2,720,153	3,215,424
CURRENT LIABILITIES			
Trade, other and related party payables	14	472,955	430,522
Borrowings	15	865,005	854,246
Total current liabilities		1,337,960	1,284,768
NON-CURRENT LIABILITIES Total non-current liabilities		-	-
		-	-
Total liabilities		1,337,960	1,284,768
Net assets		1,382,193	1,930,656

The interim financial statements are to be read in conjunction with the notes to the financial statements set out on pages 9 to 25.

### GREENFERN INDUSTRIES LIMITED INTERIM CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024

	Issued Share Capital	Accumulated Loss	Equity Holders	Options Reserve	Total
	NZ\$	NZ\$	NZ\$	NZ\$	NZ\$
Balance as at 1 April 2023	10,309,704	(7,045,719)	3,263,985	-	3,263,985
Comprehensive income					
Net loss for the financial year	-	(590,783)	(590,783)		(590,783)
Total comprehensive income	-	(590,783)	(590,783)	-	(590,783)
Transactions with owners					
Contributions of equity net of transaction costs	(5,313)	-	(5,313)	-	(5,313)
Total transactions with owners	(5,313)	-	(5,313)	-	(5,313)
Balance as at 30 September 2023 (unaudited)	10,304,391	(7,636,502)	2,667,889	-	2,667,889
Balance as at 1 April 2023	10,309,704	(7,045,719)	3,263,985	-	3,263,985
Comprehensive income					
Net loss for the financial year	-	(1,572,706)	(1,572,706)	-	(1,572,706)
Total comprehensive income	-	(1,572,706)	(1,572,706)	-	(1,572,706)
Transactions with owners Contributions of equity net of transaction costs	236,308		236,308	3,068	236,308
Total transactions with owners	236,308	-	236,308	3,068	236,308
Balance as at 31 March 2024 (audited)	10,546,012	(8,618,425)	1,930,655	3,068	1,930,655
		(0,010,120)	.,,	-,	.,,
Comprehensive income					
Net loss for the financial period	-	(654,461)	(654,461)		(654,461)
Total comprehensive income/(loss)	-	(654,461)	(654,461)	-	(654,461)
Transactions with owners					
Contributions of equity net of transaction costs	105,998	-	105,998	-	105,998
Total transactions with owners	105,998	-	105,998	-	105,998
Balance as at 30 September 2024	10,652,010	(9,272,886)	1,382,193	3,068	1,382,193

The interim financial statements are to be read in conjunction with the notes to the financial statements set out on pages 9 to 25.

### GREENFERN INDUSTRIES LIMITED CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024

		Unaudited 6 Months September	Unaudited 6 Months September 2023
	Notes	2024 NZ\$	NZ\$
Cash flows from operating activities			
Cash was received from:			
Receipts from customers		(74,868)	(275,423)
Cash receipts from related parties - trade receivables Other income received		298,776	298,776 49,677
<u>Cash was applied to:</u>		(520 504)	(400 545)
Payments to suppliers and employees Payments to related parties		(529,594) (101,722)	(498,545) (101,722)
Interest paid		(133,400)	(114,030)
Net cash outflow from operating activities		(540,808)	(641,267)
Cash flows from investing activities			
<u>Cash was received from:</u> Proceed from disposal of property, plant and equipment		_	_
Proceeds from sale of financial assets		-	-
Cash was applied to:			
Purchase of property, plant and equipment Purchase of intangible assets		171,290	50,557
Purchase of financial assets		-	-
Net cash inflow/(outflow) from investing activities		171,290	50,557
Cash flows from financing activities Cash was received from:			
Proceeds from share issue		111,311	5,313
Proceed from borrowings		-	-
<u>Cash was applied to:</u>			
Payment for share issue transaction costs		(113)	(113)
Repayment borrowings		10,759	-
Net decrease in cash and cash equivalents		10,647	(113)
Foreign currency translation adjustment		7,505	(5,273)
Cash and cash equivalents at the beginning of the year		185,808	107,400
Cash and cash equivalents at the end of the year		24,074	107,400

The interim financial statements are to be read in conjunction with the notes to the financial statements set out on pages 9 to :

#### 1. ACCOUNTING POLICIES

#### REPORTING ENTITY

Greenfern Industries Limited ("GFI") reports revenue of \$244,438 during the six-month period, which was 105% higher than the prior 6-month period ended 30 September 2024. The primary reason for this is the increase in revenuef from our cultivation facility and a decline in revenue from the Australian prescriber market arising from a change in business focus by our business partner, Cannvalate. Accordingly, GFI focussed firmly on medicinal cannabis flower production, which started to generate revenue. This has been a long-term process as the New Zealand regulations have been slower and more difficult to navigate than was expected. However, with the completion and commissioning of the company's commercial cultivation facility, it was well positioned to improve performance moving forward.

The consolidated financial statements of Greenfern Industries Limited for the six months ended 30 September 2024 comprise the Company and its subsidiaries (together referred to as the "Company"). For the purposes of complying with generally accepted accounting practice in New Zealand ("NZ GAAP"), the Company is a for-profit entity. As a listed Company, the Company is considered a Tier One entity. The principal activity of the Company is a producer and wholesaler of therapeutic products.

#### 1.1 Statement of compliance

These consolidated financial statements have been prepared in accordance with NZ GAAP. These consolidated financial statements comply with New Zealand Equivalents to International Financial reporting Standards ("NZ IFRS") and other applicable Financial Reporting Standards, as appropriate for profit oriented entities.

The consolidated financial statements were approved and authorised for issue by the directors on \_\_\_\_\_. The directors are not able to amend the financial statements after issue.

#### 1.2 Basis of preparation

#### Historical Cost Convention

The financial report has been prepared under the historical cost convention, as modified by revaluations to fair value for certain classes of assets and liabilities as described in the accounting policies.

#### Fair value measurement

For financial reporting purposes, 'fair value' is the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants (under current market conditions) at the measurement date, regardless of whether that price is directly observable or estimated using another valuation technique.

When estimating the fair value of an asset or liability, the entity uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximising the use of relevant observable inputs and minimising the use of unobservable inputs. Inputs to valuation techniques used to measure fair value are categorised into three levels according to the extent to which the inputs are observable:

- Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date.
- Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.
- Level 3 inputs are unobservable inputs for the asset or liability.

These unaudited consolidated condensed interim financial statements ('interim financial statements') have been prepared in accordance with New Zealand Generally Accepted Accounting Practice and comply with the requirements of International Accounting Standard (IAS) 34 Interim Financial Reporting and with New Zealand Equivalent to International Accounting Standard (NZ IAS) 34 Interim Financial Reporting and the NZX Main Board Listing Rules. The Company is designated as a for-profit entity for financial reporting purposes.

The interim financial statements do not include all the notes of the type normally included in an annual financial report. Accordingly, these interim financial statements should be read in conjunction with the audited consolidated financial statements for the period ended 31 March 2024 and any public announcements made by Greenfern Industries Limited during the interim reporting period and up to the date of these interim financial statements.

#### 1. ACCOUNTING POLICIES(continued)

These interim financial statements are presented in New Zealand dollars, which is the Company's functional currency and the Company's presentation currency.

The interim financial statements are in respect of the six months period from 1 April 2023 to 30 September 2024. The comparative period is in respect of the six months period 1 April 2022 to 30 September 2023. The year-end balance date will be 31 March 2025 and full financial statements will cover the 12 months period 1 April 2023 to 31 March 2025.

The preparation of the interim financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts in the interim financial statements. The estimates and underlying assumptions are based on historical experience and adjusted for current market conditions and other factors, including expectations of future events that are considered to be reasonable under the circumstances. If outcomes within the next financial period are significantly different from assumptions, this could result in adjustments to carrying amounts of the asset or liability affected. The same judgements, estimates and assumptions included in the notes to the financial statements for the full year period ended 31 March 2024 have been applied to these consolidated condensed interim financial statements.

#### 1.3 Acccounting Policies

The interim financial statements of the Company for the six months period ended 30 September 2024 have been prepared using the same accounting policies and methods of computations as, and should be read in conjunction with, the financial statements and related notes included in the Company's Annual Report for the full year period ended 31 March 2024.

#### 1.4 Material Uncertainty Relating to Going Concern

The consolidated financial statements have been prepared on a going concern basis.

The Group is in its start-up phase, and the industry in which it operates in the New Zealand and Australian markets is still in its early stages. Throughout the year, the Group's primary objective was to continue researching and developing medicinal cannabis products for mass production. As a result, the Group has reported a loss for the 6 months period to September 2024 of \$0.65 million (Sep 2023: loss of \$0.59 million).

Borrowings of \$515,900 are due to be repaid by August 2025. Before this falls due, the Directors intend to seek an extension for a further 12 month term. A non-binding agreement in principle has already been received for this. The Group has also obtained a Director Ioan of \$350,000 during the 2024 year which is due for repayment in February 2025. Again the Directors intend to seek a 12 month extension before this falls due and have already received a non-binding agreement in principle for this.

The Directors believe the going concern assumption is appropriate in light of the circumstances that, in their opinion, are likely to affect the Group for at least one year following the date the financial statements are approved.

The Directors evaluated the following factors in determining that the Going Concern assumption was appropriate:

• Board of Directors has evaluated cash flow projections for the 18 months following the date on which the financial statements were signed and has a reasonable expectation that the Group has sufficient resources to continue operating for the foreseeable future.

•As at 30 September 2024, the Group's Cash and Cash Equivalents balance was \$24,074 (March 2024: \$185,808).

• The Group raised approximately \$0.095 million in equity through wholesale allocations of shares during November 2024. The management is confident in the fundraising activities for the upcoming fiscal year 2025 due to past fundraising successes. The Group will seek further capital of \$0.8 million with its Rights Issue Offer by the end of the year, and will likely seek additional funding for specific projects and ongoing operations during the 2025/2026 financial year.

• Directors are confident that Crown Financial Services Limited and Director borrowings can be extended for an additional 12 months.

Directors have also considered the impact of:

being unable to raise capital

·being unable to extend borrowings

•delays in new cultivation production with higher quality products in the facility

While deferring planned capital expenditure and reducing operating costs can mitigate the effects, in the event that the Group is impacted by the three issues noted above a material uncertainty would exist that may cast significant doubt on the ability of the Company to continue as a going concern, and therefore, it may be unable to realise its assets and discharge its liabilities in the normal course of business.

However, the directors believe that the Company will be successful in the above matters and, on this basis, the Directors continue to adopt the going concern basis in preparing these financial statements.

Accordingly, these financial statements do not include an adjustment relating to the classification and recoverability of recorded assets amounts or the amounts and classification of liabilities that may be necessary should the Group be unable to continue as a going concern.

Accordingly, there is a material uncertainty around going concern, which heavily depends on a successful:

capital raising

borrowing extensions

•New reset programme on the cultivation processes for higher yield and quality

2. REVENUE

		September 2024	September 2023
	Note	NZ\$	NZ\$
Operating revenue			
Sales - Hemp Meal		27,000	7,859
Sales - MaTo		567	1,081
Sales - Licensed Fees		-	101,495
Sales of Electricity		-	2,842
Other Income		216,871	6,113
Total operating revenue	_	244,438	119,390
Research and Development Tax Credit		-	48,830
Total other income	-	-	48,830
Total Income	-	244,438	168,220

#### Performance Obligations and Revenue Recognition

Revenue is measured based on the consideration specified in a contract with a customer. The Company recognises revenue when it transfers control over a good or service to a customer.

#### **Operating revenue - Geographical locations**

Operating revenue is attributed to the following geographical locations on the basis of the country the customer is trading in.

		Sales of	
	Sales of Goods	Electricity	Total
	NZ\$	NZ\$	NZ\$
30 September 2024			
Australia	-	-	-
New Zealand	244,438	-	244,438
Operating Revenue	244,438	-	244,438
30 September 2023			
Australia	101,495	-	101,495
New Zealand	15,053	2,842	17,895
Operating Revenue	116,548	2,842	119,390

#### 3. EXPENSES

	Note	September 2024 NZ\$	September 2023 NZ\$
Profit / (Loss) before income tax has been	Hoto	nev.	
Included in Cost of Sales Expenses			
Direct purchase cost of goods sold		36,970	15,821
Overhead allocated		103,551	15,813
Total Cost of Sales	-	140,521	31,634
Included in Selling and Distribution Expenses			
Marketing & Advertising		-	580
Other expense		12,000	20,934
Total Selling and Distribution Expenses	-	12,000	21,514
Included in Administration Expenses			
Salaries		167,153	221,170
R&D expenses		13,338	69,544
Directors Fees		61,793	88,750
Depreciation and Armotisation	10, 12	128,674	106,577
Repairs and Maintenance		-	7,924
Bad Debts		63,431	-
Share Register Expense		7,557	14,271
Low Value Assets		1,605	7,647
Legal expenses		6,034	8,356
Licence Fees		15,421	7,679
Insurance		35,577	33,710
Rent	22	3,748	13,083
Consulting		95,996	11,300
Other expenses		67,296	57,305
Total Administration Expenses	=	667,622	647,317
Finance costs:			
Interest paid on use of money		78,756	59,386

The majority of interest came from the loan of a related party (note 15).

#### INCOME TAX EXPENSE 4.

The Company recognised no income tax expense during this period due to operating loss. The Company has an income tax rate of 28% which is the tax rate that would be applicable to the expected total annual earnings (September 2023: 28%).

The Company has an unused tax losses of \$2,138,176 bought forward from 31 March 2024. Losses can be carried forward indefinitely under New Zealand tax law (assuming shareholder continuity requirements are met and approval of the Inland Revenue Department is obtained).

The Company has not recognised a deferred tax asset on its Statement of Financial Position as at reporting date. In deciding whether to recognise the deferred tax assets, the Company has determined if the utilisation of deferred assets is probable and whether it is likely that sufficient and suitable taxable profits will be available in the future against which the reversal of temporary differences can be deducted.

#### EARNINGS PER SHARE 5.

The earnings and weighted average number of ordinary shares used in the calculation of basic earnings per share are as follows: .

	September 2024 NZ\$	September 2023 NZ\$
Basic earnings per share Profit/ (Loss) after taxation attributable to equity holders of the parent Weighted average number of ordinary shares on issue	(654,461) 117,038,203	(590,784) 109,857,152
Basic and Diluted Earning per share in NZ\$	(0.00559186)	(0.00537775)

The Company is listed and its ordinary shares are quoted on the NZX main board equity security market (NZX main market) at 21 October 2021. There have been other transactions involving ordinary shares or potential ordinary shares between the reporting date and the date of authorisation of these financial statements(as disclosed in note 23).

#### AUTHORISED AND ISSUED SHARE CAPITAL 6.

Ordinary shares		
Balance as at 31 March 2024	Shares Issued No.	\$
<b>Ordinary shares</b> Balance at 1 April 2023		Ψ.
Ordinary shares on issue	109,857,152	10,309,704
Ordinary shares on issue at 1 April 2023 excluding treasury shares	109,857,152	10,309,704
Movement for 2024 financial year		
Gross ordinary shares authorised and issued Transaction costs on ordinary shares authorised and issued	5,157,479	255,034 (18,726)
Net ordinary shares authorised and issued	5,157,479	236,308
Ordinary shares on issue at 31 March 2024	115,014,631	10,546,012
Ordinary shares Balance as at 31 March 2024	Shares Issued No.	NZ\$
Balance at 1 April 2024	115,014,631	10,546,012
Movement for 2024 financial year		
Gross ordinary shares authorised and issued Transaction costs on ordinary shares authorised and issued	4,047,144	105,998
Net ordinary shares authorised and issued	4,047,144	105,998
Ordinary shares on issue at 30 September 2024	119,061,775	10,652,010
Ordinary shares on issue at 30 September 2024 excluding treasury shares	119,061,775	10,652,010

**.** . .

### 6. AUTHORISED AND ISSUED SHARE CAPITAL(continued)

GFI was under the process of wholesale offer to raise captial, more detail was disclosed in note 23.

All ordinary shares rank equally with one vote attached to each fully paid ordinary share and have equal dividend rights and no par value. No dividends have been declared or paid for the six months ended 30 September 2024 (2023: \$nil).

At reporting date, the Company held no treasury shares.

#### 7. CASH AND CASH EQUIVALENTS

	September 2024 \$	March 2024 \$
Cash at bank and on hand	<u>24,074</u>	185,808
Total cash and cash equivalents	<b>24,074</b>	<b>185,808</b>

The carrying amount of cash and cash equivalents approximates their fair value.

#### 8. TRADE, OTHER AND RELATED PARTY RECEIVABLES

		September 2024	March 2024
	Note	NZ\$	NZ\$
Trade receivables - third parties		66,998	(152,122)
Trade receivables - related parties		7,650	302,277
Provision for bad debts		(72,923)	
Total trade and related party receivables	=	1,725	150,155
Analysis of trade and related party receivables			
Current		-	135,432
Past due 0-30		-	-
Past due 31-90		-	-
Past due more than 90		1,725	14,723
	—	1,725	150,155

Trade debtors are non-interest bearing and receipt is normally on 30 days terms. Related party receivables are non-interest bearing and repayable on demand as disclosed in note 14.

The directors consider that there is no material difference between the carrying value and fair value of trade debtors and related party receivables after provisioning for bad debts in relation to Sustainable Foods (\$32,646) and Cannvalate Pty Limited (\$40,277) in full. The Company's management considers that all financial assets that are not impaired or past due for each of the reporting dates under review are of good credit quality after the provision for bad debts of \$72,923 in total. The directors also consider that the receivables that are past due and not impaired (\$1,725) are fully recoverable.

The Company applies both a specific loss component and a collective loss component in determining the allowance for impairment or bad debt. The specific loss component considers and relates to individually significant exposures and the collective loss component is based on expected losses that are established for group of similar assets. The collective loss allowance is determined based on historical data of payment statistics for similar financial assets. The Company also considers other forward looking economic factors in determining the impairment of trade, other and related party receivables. The impairment allowance or provision for bad debts of \$72,923 has been recognised for the six months ended 30 September 2024 (2023: \$nil).

#### 9. PREPAYMENTS AND OTHER CURRENT ASSETS

	Note	September 2024 NZ\$	March 2024 NZ\$
Current Prepayments			
Prepayments to other suppliers		10,171	50,130
GST receivable		8,749	10,117
Total current prepayments		18,920	60,247

### 10. PROPERTY, PLANT AND EQUIPMENT

	Office Equipment <b>NZ\$</b>	Power Station NZ\$	Power Station Land <b>NZ\$</b>	Facility Taranaki <b>NZ\$</b>	Assets under construction - work in progress NZ\$	Motor Vehicles NZ\$	Total NZ\$
As at 31 March 2024							
Cost							
Cost as at 1 April 2023	47,530	897,330	-	1,409,279	392,328	-	2,746,467
Transfers from work in progress	-	-	-	250,670	-	-	250,670
Transfers to property, plant and equipment	-	(59,000)	59,000	-	(250,670)	-	(250,670
Disposals	(3,471)	-	-	-	-	-	(3,471
Additions	-	71,601	-	428,887	11,539	20,500	532,527
Cost as at 31 March 2024	44,059	909,931	59,000	2,088,836	153,197	20,500	3,275,523
Accumulated Depreciation							
Accumulated depreciation at 1 April 2024	(26,435)	(51,245)	-	(177,483)	-	-	(255,163
Disposal	-	-	-	-	-	-	-
Depreciation charge for the period	(1,107)	(38,994)	-	(210,833)	-	(1,025)	(251,959)
Accumulated Depreciation at 31 March 2024	(27,542)	(90,239)	-	(388,316)	-	(1,025)	(507,122
Carrying Amount							
Cost	44,059	909,931	59,000	2,088,836	153,197	20,500	3,275,523
Accumulated Depreciation	(27,542)	(90,239)	-	(388,316)	-	(1,025)	(507,122
Carrying Amount 31 March 2024	16,517	819,692	59,000	1,700,520	153,197	19,475	2,768,401
As at  30 September 2024 Cost	44.059				156,722		
Cost as at 1 April 2024	44.059	909,931	59.000	2.088.836	153,197	20.500	3,275,523
Transfers from work in progress	-			_,	-		-,,
Transfers to property, plant and equipment	-	-	-	-	-	-	-
	_	_	_	_		_	
Disposal Additions				5.999	3,525		9,524
Cost as at 30 September 2024	44,059	909,931	59,000	2,094,835	156,722	20,500	3,285,047
Accumulated Depreciation at 1 April 2024	(27,542)	(90,239)		(388,316)		(1,025)	(507,122
Disposals	(27,342)	(30,233)	-	(300,310)	-	(1,023)	(307,122
Disposais Depreciation charge for the period	-	-	-	-	-	-	
Depreciation charge for the period	(2,795)	(18,230)	-	(104,252)	-	(2,921)	(128,198
Accumulated Depreciation at 30 September 2024	(30,336)	(108,469)	-	(492,568)	-	(3,946)	(635,320
Carrying Amount							
Cost	44,059	909,931	59,000	2,094,835	156,722	20,500	3,285,047
Accumulated Depreciation					-	-	(635,319
· · · · · · · · · · · · · · · · · · ·	(30,336)	(108,469)	-	(492,568)	-	(3,946)	(000,019
Carrying Amount 30 September 2024	13,723	801,462	59.000	1,602,267	156,722	16.554	2.649.728

#### 11. BARTERCARD

	September 2024 NZ\$	March 2024 NZ\$
Bartercard balance	14,181	16,758

Bartercard trade dollars comprise the balance of Bartercard Trade Dollars on hand at period end net of accumulated impairment losses. Trade dollars are not transferable for cash by Bartercard or any other financial institution.

Bartercard trade dollars was equivalent to the carrying value of the assets. Carrying value was determined based on the fact that all market participants (being other Bartercard members) accept the terms and conditions of Bartercard which stipulate that a Bartercard Trade Dollar is equivalent to a New Zealand dollar at the date of exchange in respect of future purchases or goods and services.

### 12. INTANGIBLE ASSETS

	Graphic design <b>NZ\$</b>	Trademarks <b>NZ\$</b>	Total <b>NZ\$</b>
Year ended 31 March 2024			
Cost			
Cost as at 1 April 2023	10,162	2,650	12,812
Additions	-	-	
Cost as at 31 March 2024	10,162	2,650	12,812
Accumulated Amortisation			
Accumulated amortisation 1 April 2023	(1,430)	(828)	(2,258)
Amortisation for the year	(873)	(182)	(1,055)
Accumulated amortisation and impairment as at 31			
March 2024	(2,303)	(1,010)	(3,313)
Carrying Amount			
Cost	10,162	2,650	12,812
Accumulated amortisation and impairment	(2,303)	(1,010)	(3,313)
Carrying Amount 31 March 2024	7,859	1,640	9,499
Cost			
Cost as at 1 April 2024	10,162	2,650	12,812
Additions	(35)	(400)	(435)
Cost as at 31 September 2024	10,127	2,250	12,377
Accumulated Amortisation			
Accumulated amortisation 1 April 2024	(2,303)	(1,010)	(3,313)
Amortisation for the period	(359)	318	(41)
Accumulated amortisation and impairment as at 30 September 2024	(2,662)	(692)	(3,354)

### 12. INTANGIBLE ASSETS (continued)

	Graphic design <b>NZ\$</b>	Trademarks <b>NZ\$</b>	Total <b>NZ\$</b>
Carrying Amount			
Cost	10,127	2,250	12,377
Accumulated amortisation	(2,662)	(692)	(3,354)
Carrying Amount as at 30 September 2024	7,465	1,558	9,023

#### 13. OTHER FINANCIAL ASSETS

Non-current assets	September 2024 NZ\$	March 2024 NZ\$
Financial assets measured at amortised cost		
<u>Shares in unlisted companies</u> Hempseed Holdings Limited	200	200
	200	200
Total financial assets measured at amortised cost	200	200
Total other financial assets	200	200

### Fair value movement in profit and loss

During the six months ended 30 September 2024, no fair value gains/(losses) were identified and recognised in the profit and loss.

#### 14. TRADE, OTHER AND RELATED PARTY PAYABLES

	Note	September 2024 NZ\$	March 2024 NZ\$
Trade and other payables		412,847	336,015
Related party payables		50,391	65,815
Employee entitlements		9,717	28,692
Total trade, other and related party payables		472,955	430,522

The normal trade credit terms granted to the Company range from 30 to 90 days. The trade creditors are unsecured and non-interest bearing. The carrying amount disclosed above is a reasonable approximation of fair value.

#### 15. LOAN

	Note	September 2024 NZ\$	March 2024 NZ\$
Current			
Crown Financial Services Limited		515,900	515,900
Directors Loan		100,000	50,000
Jasper Mace		250,000	250,000
Frank Risk Management (Wellington) Limited		895	38,346
Total Ioan		866,795	854,246

The \$515,900 one-year loan was borrowed from a related party of the Company (Crown Financial Services Limited) in August 2022 and extended for a further year from August 2023 and August 2024 each year.

#### 16. RELATED PARTIES

#### **Related Parties:**

### Parent and ultimate controlling party

The immediate parent of the Group is Greenfern Industries Limited. By virtue of the fact the Company is owned by a large number of small investors; there is no ultimate controlling party.

#### **Subsidiaries**

Greenfern Industries Limited has a related party relationship with the subsidiaries and associates as listed at note 22.

Cannvalate Pty Limited	Shareholder and entity controlled by director Darryl Davies
Crown Financial Services Limited	Shareholder and entity controlled by director Marvin Yee
Omega Corporation Limited	Common directorship by director Marvin Yee
Explore and Discover Pty Limited ATF the Davies Family Trust	Company associated to company's director Darryl Davies
Mitakuye Owasin Trust	Entity controlled by contractor as a consultant whom we have a commercial agreement with AmovI Sciences
Prime Assets Limited	Shareholder and entity controlled by director Phillip Wesley Brown

#### Related party balances

The following balances were held with related parties at period end.

		September	March
		2024	2024
	Nature of Transactions	NZ\$	NZ\$
Related Party Receivables			
Cannvalate Pty Ltd	License fees	-	143,120

#### Related Party Payables

Crown Finanical Services Limited	Interest accrued	15,993	62,940
Omega Corporation Limited	Director fee	43,125	34,500
Dan Casey, Jasper Mace and Kirsten Taylor	Interest accrued	10,675	-
Prime Assets NZ Limited	Director fee	2,875	2,875
	-	72,668	100,315

143,120

-

#### 16. RELATED PARTIES (continued)

	September	March
	2024	2024
Nature of Transactions	NZ\$	NZ\$

Berrowings			
Crown Financial Services Limited	Loan	515,900	515,900
Jasper Mace	Loan	250,000	250,000
Kirsten Taylor	Loan	50,000	50,000
Dan Casey	Loan	50,000	-
	-	865,900	815,900

The related parties balances are non-interest bearing and unsecured. There is no collateral or guarantees for related parties receivables & payables. Borrowings are interest bearing and secured.

#### Related party transactions:

		September 2024	September 2023
Related party transactions	Nature of Transactions	NZ\$	NZ\$

#### Sales of products or services provided to the following:

Cannvalate Pty Ltd	Licensed fees & products	-	101,495
		•	101,495

### Purchases from the following for services, products provided:

Cannvalate Pty Ltd	Patient acquisition fees	-	57,078
Crown Financial Services Limited	Fees & Interest	47,205	58,280
Jasper Mace	Interest	22,875	-
Kirsten Taylor	Interest	4,575	-
Dan Casey	Interest	2,400	-
Mitakuye Owasin Trust	Consulting	-	7,300
		77,055	122,658

Directors Fees		
Omega Corporation Limited	22,500	16,250
Explore and Discover Pty Ltd ATF the DT Davies Family Trust	-	7,500
Prime Assets NZ Limited	-	16,250
Dan Casey	-	15,000
Kirsten Taylor	15,000	15,000
Simon Mcarley	18,750	18,750
	56,250	88,750
Loan received/repayment		
Crown Financial Services Limited	-	#

Crown Financial Services Limited	-	

#### 16. RELATED PARTIES (continued)

#### Key Management Personnel

Key management personnel are defined as those persons having authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly, and include the directors, chief executive and senior management. Remuneration paid to key management personnel is as follows:

	September	September
	2024	2023
	NZ\$	NZ\$
Salaries and other short-term benefits	68,654	134,164
Director fees	-	56,250
Total	68,654	190,414

#### 17. COMMITMENTS AND CONTINGENCIES

The Company has no capital commitments and contingencies at 30 September 2024.

#### **18. FINANCIAL INSTRUMENTS**

The Company is exposed to the following financial risks in respect to the financial instruments that it held at the end of the reporting period:

- (a) Credit risk(b) Capital management(c) Liquidity risk
- (d) Other market risk
- (e) Interest rate risk

(f) Fair values compared with carrying amounts

The board of directors have overall responsibility for identifying and managing operational and financial risks.

#### Categories of financial assets and liabilities

The carrying amounts presented in the statement of financial position relate to the following categories of assets and liabilities:

	September 2024	March 2024
	NZ\$	NZ\$
Financial Assets:		
Amortised cost		
Cash and cash equivalents	24,074	185,808
Trade and related party receivables	74,648	150,155
Provision for bad debts	(72,923)	-
Fair value through profit or loss		
Shares in unlisted entities	200	200
Total financial assets	25,999	336,163
Financial liabilities:		
Amortised cost		
Trade and other payables	463,238	430,522
Loan	865,900	815,900
Total financial liabilities	1,329,138	1,246,422

#### 18. FINANCIAL INSTRUMENTS(continued)

The specific financial risks that the Company is exposed to are discussed below.

#### (a) Credit risk

Financial instruments which potentially are subject to credit risk principally relate to bank accounts, trade receivables and other receivables. Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation.

Credit risk arises from balances held with banks. The credit risk is managed by holding all cash and cash equivalents with a New Zealand registered bank.

The Company's receivables balance are small. The maximum exposure to credit risk, excluding the value of any collateral or other security, at balance date of recognised financial assets is the carrying amount of those assets, net of any provisions for impairment of those assets, as disclosed in consolidated statement of financial position and notes to financial statements.

#### Exposure to credit risk

As the Company does not hold any collateral, the maximum exposure to credit risk is represented by the carrying amount of the financial assets as at the end of the reporting period.

The exposure of credit risk for trade and other receivables by geographical region is as follows:

	September 2024 NZ\$	March 2024 NZ\$
Australia New Zealand	- 1,725	143,120 7,035
Total trade and related party receivables	1,725	150,155

#### Expected credit loss assessment

The impairment allowance or provision for bad debts of \$72,923 has been recognised recognised in this period (2023: \$nil) based on the NZ IFRS 9 expected loss model assessment.

#### (b) Capital management

The capital structure of the Company consists of equity attributable to equity holders of the parent, comprising of issued capital and retained earnings. The Company's capital includes share capital net of accumulated losses with total shareholders' funds equal to \$1,445,601 (March 2024: \$1,930,656). The Board reviews the Company's capital structure regularly. The capital of the Company is monitored to ensure equity holder objectives are met, the primary of which is to ensure the Company provides a consistent return to its equity shareholders through a combinations of capital growth and distributions. The Company manages its capital to ensure the entities in the Company will be able to continue as going concerns. The current capital raising activities are as described in Note 23.

#### (c) Liquidity risk

Liquidity risk is the risk that an entity will encounter difficulty in meeting obligations associated with financial liabilities.

The Company considers expected cash flows from financial assets in assessing and managing liquidity risk, in particular its cash resources, trade receivables and the provision of funding from related parties and bank loan facilities.

#### 18. FINANCIAL INSTRUMENTS (continued)

The following table outlines the Company's remaining contractual maturities for non-derivative financial instruments. The amounts presented in the table are the undiscounted contractual cash flows of the financial liabilities, allocated to time bands based on the earliest date on which the Company can be required to pay.

	0 to 6 months NZ\$	7 to 12 months NZ\$	1 to 2 years NZ\$	Over 2 years NZ\$	Total NZ\$
2024 September Financial liabilities:					
Trade creditors and other payables	463,238	-	-	-	463,238
Borrowings	865,900	-	-	-	865,900
	1,329,138	-	-	-	1,329,138
<b>2024 March</b> <u>Financial liabilities:</u>					
Trade and other payables	430,522	-	-	-	430,522
Borrowings	854,246	-	-	-	854,246
	1,284,768	-	-	-	1,284,768

#### (d) Other market risk

Other market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices (other than those arising from interest rate risk or currency risk).

The Company faces the risk that the supply of cannabis products available in New Zealand will outstrip the demand, which may result in lower product prices, which in turn may have an adverse effect on the Company's financial performance.

#### (e) Interest rate risk

Interest rate risk is where the risk of loss to the Company from adverse changes in interest rates. The Company is exposed to interest rate risk if the Company is unable to repay its interest-bearing loan on time.

#### (f) Fair value of financial assets and liabilities

The fair value of financial assets and financial liabilities approximates their carrying amounts as disclosed in consolidated statement of financial position and notes to financial statements. The fair value of financial assets and financial liabilities are determined using standard terms and conditions of the relevant instruments.

#### 19. INVESTMENT IN SUBSIDIARIES

#### (a) Subsidiaries

Name of subsidiary	Country of Incorporation	Principal activity	Ownership intere rights	•
			September 2024	March 2024
GFI Pharma Limited	New Zealand	Non-Trading	100%	100%
Greenfern Hemp Limited	New Zealand	Non-Trading	100%	100%
Greenfern Power Limited	New Zealand	Non-Trading	100%	100%
Mato Limited	New Zealand	Non-Trading	100%	100%
Greenfern Cultivation Limited	d New Zealand	Non-Trading	100%	100%
GFI Pharma Pty Limited	Australia	Non-Trading	100%	100%

#### 19. INVESTMENT IN SUBSIDIARIES (continued)

Ownership interest are the same as voting rights. All subsidiaries were incorporated in March 2021 and are non trading.

#### (b) Associates

Associate	Measurement basis	Quoted Fair value (if available)		Ownership interest rights	and voting
		September 2023	March 2023	September 2023	March 2023
Greenfern Industries Thailand	Equity Accounted	-	-	49%	49%

Greenfem Industries Thailand was incorporated in Thailand in 1 September 2020. The company is non trading. Greenfem Industries Limited (NZ) recognised \$nil profit or loss from the associate.

#### 20. SEGMENT REPORTING

The Company's operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker. The chief operating decision-maker is the person or group that allocates resources to and assesses the performance of the operating segments on an entity. The Company has determined the Company's Board of Directors as its chief operating decision-maker as the board is responsible for allocating resources and assessing the performance of the operating segments and making strategic and operating decisions. Income and expenses directly associated with each segment are included in determining each segment's performance.

The Company operates in a number of business segments in New Zealand and Australia. The Company has determined its operating segments into two segments which reflect the different type of industry sectors within which the Company operates. Information regarding the operations of each reportable operating segment is included below.

#### Cannabis and therapeutics products

The operations of this segment reflect the activities of manufacture and distribution of cannabis products.

#### Electricity generation

This segment includes the generation and distribution of electricity.

No operating segments have been aggregated to form the above reportable operating segments. There were no sales between segments of the Company during the year.

The following tables present revenue and profit information for the Company's operating segments for the six months ended 30 Septembr 2024 and 2023, respectively:

### 20. SEGMENT REPORTING (continued)

For the six months ended 30 September 2024 Operating Income External Operating Revenue from customers Other Revenue Finance Income Total Revenue		244,438		
External Operating Revenue from customers Other Revenue Finance Income		244,438		
Other Revenue Finance Income	-	244,438		
Finance Income	-		-	244,438
		-	-	-
Total Revenue	-	-	-	-
	-	244,438	-	244,438
Cost of sales	-	110,976	29,545	140,521
Operating Expenses				
Salary expenses	167,153	-	-	167,153
Depreciation	6,192	104,252	18,230	128,674
Finance Expense	78,756	-	-	78,756
(Gain)/Loss on Fixed Asset Disposal	-	-	-	-
Other expenses	383,795	-	-	383,795
Total operating expenses	635,896	104,252	18,230	758,378
Segment profit/(loss) before tax	(635,896)	29,210	(47,775)	(654,461)
For the six months ended 30 September 2023				
Operating Income				
External Operating Revenue from customers	-	116,548	2,842	119,390
Other Revenue	-	48,830	_,0	48,830
Finance Income	847	-	_	847
Total Revenue	847	165,378	2,842	169,067
Cost of sales	-	23,509	8,125	31,634
Operating Expenses				
Salary expenses	108,144	94,957	18,068	221,170
Depreciation	(225,492)	267,414	64,655	106,577
Finance Expense	59,386	-	-	59,386
(Gain)/Loss on Fixed Asset Disposal	1,787	-	-	1,787
Other expenses	233,916	100,564	4,817	339,297
Total operating expenses	177,741	462,935	87,541	728,217
Segment profit/(loss) before tax	(176,894)	(321,066)	(92,824)	(590,784)

#### **Geographical segments**

Revenue from external customers is attributed to geographical segments on the basis of the country the customer is trading in. Revenues from one related party customer of the Company's Cannabis and therapeutics products segment represented 85% (2022: 80%) of the Company's total operating revenue.

	September 2024	September 2023
External Operating Revenue	NZ\$	NZ\$
Australia	-	101,495
New Zealand	244,438	17,895
External Operating Revenue	244,438	119,390

#### 20. SEGMENT REPORTING (continued)

All assets, and liabilities were domiciled within New Zealand and Australia. The following tables present assets and liabilities information for the Company's operating segments as at 30 September 2024 and 31 March 2024, respectively:

	Unallocated	Cannabis and therapeutics products	Electricity generation	Total
	NZ\$	NZ\$	NZ\$	NZ\$
As at 30 September 2024				
Segment assets	61,201	1,614,498	1,019,152	2,694,850
Capital Expenditure		2,076,605	-	2,076,605
Segment Liabilities	1,009,192	320,019	-	1,329,211
As at 31 March 2024				
Segment assets	391,860	1,850,675	972,889	3,215,424
Capital Expenditure	20,500	428,887	83,140	532,527
Segment Liabilities	1,151,995	9,402	103,371	1,264,768

#### 21. NET TANGIBLE ASSETS PER SHARE

The net tangible assets and number of shares are as follows:

	Note	September 2024 NZ\$	March 2024 NZ\$
Total assets Less intangible assets		2,720,153 9,024	3,215,424 9,499
Tangible assets		2,711,129	3,205,925
Less total liabilities		1,337,960	1,284,768
Net tangible assets		1,373,169	1,921,157
Number of ordinary shares on issue	6	119,061,775	115,014,631
Net tangible assets / liabilities per share in NZ\$		0.01153325	0.01670359

#### 22. LEASES

#### Short-term leases and leases for low value assets

The Company has elected not to recognise a right-of-use asset and corresponding lease liability for short-term leases with terms of 12 months or less and leases of low-value assets. Lease payments on these assets are expensed to profit or loss as incurred on a straight line basis.

Lease payments for the following short-term leases and leases for low value assets expensed to profit or loss on a straight line basis are as follows:

	September 2024 NZ\$	September 2023 NZ\$
Lease of motor vehicle Lease of plant and equipment Lease of land Lease of desk space	- 1,409 2,400	8,112 2,570 2,400
	<u> </u>	-
	3,809	13,083

The Company has no other leases or right of use assets.

#### 23. EVENTS AFTER THE REPORTING PERIOD

The outcome of the Company's current capital raising activities was as below:

#### Wholesale Offer

In November 2024, the Company has completed wholesale placements raising \$90,000 by issuing 4,090,909 ordinary shares at \$0.022 per share, together with 2,045,455 options to subscribe for an additional ordinary share at \$0.022 at any time in the following 12 months.

The company is actively pursuing further wholesale capital raising opportunities in the coming months to fund its activities until revenue from its commercial cultivation facility becomes sufficient to meet its operating expenses.

There has been no other matter or circumstance, which has arisen since 30 September 2024 that has significantly affected or may significantly affect:

- (a) the operations, in financial years subsequent to 30 September 2024, of the Company, or
- (b) the results of those operations, or
- (c) the state of affairs, in financial years subsequent to 30 September 2024, of the Company.

#### 24. SEASONALITY OF INTERIM OPERATIONS

There are no significant seasonality or cyclicality of business affecting the interim operations.

### GREENFERN INDUSTRIES LIMITED CORPORATE INFORMATION

### FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024

SOLICITORS FLACKS & WONG PO Box 591 Level 5, Shortland Chambers Building 70 Shortland Street, Auckland

#### SHARE REGISTRAR

Computershare Investor Services Limited Level 2, 159 Hurstmere Road Private Bag 92-119 Auckland 1142

#### AUDITORS

AD Danieli Audit Pty Limited Level 1, 261 George Street Sydney, NSW 2000

#### BANK

BNZ Bank Hamilton Store Garden Place 354 Victoria Street Hamilton Phone 0800 275 269

#### **Greenfern Industries Limited**

Security code: GFI Listed on NZX Market NZ Company number: 6804155

#### HEAD OFFICE / REGISTERED OFFICE

Greenfem Industries Limited Level 5, 17 Albert Street Auckland 1040 New Zealand

**TELEPHONE** +64 (27) 244 2826

WEBSITE www.gfi.nz